Warning: Missing argument 1 for get_pagelink_by_slug(), called in /export/sd09/www/jp/r/e/gmoserver/7/3/sd0131973/jpcnma.or.jp/wp-content/themes/jpcnma/header.php on line 127 and defined in /export/sd09/www/jp/r/e/gmoserver/7/3/sd0131973/jpcnma.or.jp/wp-content/themes/jpcnma/admin/functions-theme-basic.php on line 98



前言 寄语“日中乳腺癌治疗最前沿”特辑

国际医疗福祉大学三田医院乳腺中心 主任


中国医学科学院肿瘤医院、国家癌症中心 乳腺外科
徐晓洲※1  刘嘉琦
※1 主任医师

Advances and trends in surgical treatment of breast cancer in China

Breast cancer has become the most common malignant disease in women globally and in China. With the development of multi-disciplinary treatment, which combines chemotherapy, radiotherapy, anti-HER2, and endocrine therapy, Chinese breast cancer patients get a better prognosis. Therefore, there is a trend of individualized comprehensive treatment which means less damage and better postoperative cosmetic effects for surgical treatment of breast cancer. Currently, breast-conserving therapy and sentinel lymph node biopsy has become the first choice for eligible early breast cancer patients. However, there are still controversies in the selection and specification of indications for oncoplastic breast surgery, breastconserving surgery combined with intraoperative radiotherapy, endoscopic or robot-assisted breast cancer surgery, and breast cancer surgery for advanced breast cancer patients. Thus, further studies are still needed. In addition, the COVID-19 epidemic poses new challenges to the surgical treatment of breast cancer patients in China.

【Key words】
Breast cancer, Breast-conserving surgery, Oncoplastic breast surgery, Sentinel lymph node biopsy, Surgical treatment


复旦大学附属肿瘤医院乳腺癌研究所 教授

Current Status of Gene Therapy for Breast Cancer in China

Identification of breast cancer susceptibility gene BRCA mutation, multi-gene assay with MammaPrint, combination of targeted therapy against HER2, PD-1 and so on and traditional strategies including chemotherapy, independent research and development of epigenetic drugs and a novel classification of triple negative breast cancer reflected the historic progress of gene therapy for breast cancer in China and greatly improved the clinical diagnosis and treatment of breast cancer. It also brings hope to conquer breast cancer, the most common malignant tumor around the world, in the near future.

【Key words】
Breast cancer, Gene therapy, Molecular subtypes, Oncogene, Tumor suppressor gene


明石定子※1  松柳美咲※2
※1 教授 ※2 助教

The front line of breast cancer treatment in Japan

Personalized medicine for operable breast cancer is developing, and de-escalataion for early breast cancer / escalation for advanced breast cancer are spreading. Genetic tests for BRCA 1/2 mutation had been covered by Japan medical insurance in 2020, so the number of preoperative genetic tests increased. Medical staff should be aware of specific managements including risk reducing surgery and intensive surveillance for HBOC patients and their family members.

【Key words】
breast surgery, hereditary breast and ovarian cancer syndrome, neoadjuvant chemotherapy


东京大学研究生院医学系研究科乳腺内分泌外科学 副教授
东京大学医学系附属医院乳腺内分泌外科 科长

The front line of precision medicine for breast cancer in Japan

Precision medicine in breast cancer as well as in various cancers has been performed in daily clinical practice. The primary purpose of cancer genome analysis is to find genetic alterations which could be direct targets of molecular-targeted treatments or clinical trials. In this analysis, germline variants associated with hereditary cancers are occasionally detected. Such findings are called incidental or secondary findings, requiring appropriate assessment, including genetic counseling. Here, I summarized precision medicine in breast cancer.

【Key words】
breast cancer, precision medicine, Todai OncoPanel


纽 带

朝日大学 校长

笹川生 in China

海南省人民医院心血管内科 主任医师
吴 忠

后 记 宣传委员会委员  野泽宏彰